Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | PNP | P00491 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyinosine SCHEMBL29357821 | 0.94 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL7191121 | 0.94 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL2000526 | 0.94 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL324457 | 0.94 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL24307 | 0.94 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL5982293 | 0.94 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL29733324 | 0.93 | HIF1A (0.71) | HIF1APNPLMNATP53HTT | |
| Deoxyadenosine SCHEMBL8581593 | 0.90 | HIF1A (0.65) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL28172526 | 0.89 | HIF1A (0.64) | HIF1APNPLMNATP53HTT | |
| Deoxyadenosine SCHEMBL2986950 | 0.89 | HIF1A (0.66) | HIF1APNPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716253-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8476416-B2 | comprises a dinucleotide analog that includes a non-naturally occurring pyrimidine base; for treating autoimmune disorders, such as autoimmune asthma; allergies | IDERA PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8030462-B2 | Immunotherapy; induce immunology response | IDERA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-7932367-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2292632-A2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | Idera Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7833538-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7824696-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7790168-B2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080027214-A1 | Modulation of immunostimulatory activity of immunostimulatory Oligonucleotide analogs by positional chemical changes | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2008-01-31 | — | — | US | disclosed |
| EP-1322656-B1 | MODULATION OF IMMUNOSTIMULATORY ACTIVITY OF IMMUNOSTIMULATORY OLIGONUCLEOTIDE ANALOGS BY POSITIONAL CHEMICAL CHANGES | IDERA PHARMACEUTICALS INC (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070072198-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1736479-A2 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | Idera Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060142224-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2006-06-29 | — | — | US | disclosed |
| US-20060135454-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2006-06-22 | — | — | US | disclosed |
| US-20050026858-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2005-02-03 | — | — | US | disclosed |
| US-20040266709-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2004-12-30 | — | — | US | disclosed |
| US-20040266710-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2004-12-30 | — | — | US | disclosed |
| EP-1322656-A2 | MODULATION OF IMMUNOSTIMULATORY ACTIVITY OF IMMUNOSTIMULATORY OLIGONUCLEOTIDE ANALOGS BY POSITIONAL CHEMICAL CHANGES | HYBRIDON, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2002-09-26 | — | — | US | disclosed |
| WO-2002026757-A2 | MODULATION OF IMMUNOSTIMULATORY ACTIVITY OF IMMUNOSTIMULATORY OLIGONUCLEOTIDE ANALOGS BY POSITIONAL CHEMICAL CHANGES | HYBRIDON, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027214-A1 | Modulation of immunostimulatory activity of immunostimulatory Oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | HIF1A 2702/4885PNP 921/4885LMNA 4812/4885 |
| US-20040266709-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | HIF1A 2702/4885PNP 921/4885LMNA 4812/4885 |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | HIF1A 2702/4885PNP 921/4885LMNA 4812/4885 |
| US-20040266710-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | HIF1A 2702/4885PNP 921/4885LMNA 4812/4885 |
| US-20060135454-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | HIF1A 2702/4885PNP 921/4885LMNA 4812/4885 |
| US-20050026858-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | HIF1A 2702/4885PNP 921/4885LMNA 4812/4885 |
| US-20060142224-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | HIF1A 2702/4885PNP 921/4885LMNA 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.